Baseline characteristics
| Characteristic . | All patients (N = 34) . |
|---|---|
| Age, median (range), y | 20 (15-52) |
| Age 15-25 y | 24 |
| Age <35 y | 28 |
| Age >35 y | 6 |
| Risk group | |
| Standard risk | 14 (41%) |
| High risk | 20 (59%) |
| Male:female sex | 26:8 |
| ECOG performance status >1 | 6 (17.6%) |
| White blood cell count ≥30 × 109/L | 7 (20.6%) (range, 30-70 × 109/L) |
| CNS involvement | 10 (29.4%) |
| Flow cytometry alone | 10 (29.4%) |
| Cytomorphology and flow cytometry | 5 (14.7%) |
| CD20%, median (range) | 75% (20%-100%) |
| Cytogenetic features | |
| Diploid | 12 (34%) |
| Hyperdiploidy | 9 (25%) |
| Hypodiploidy | 6 (17%) |
| Ploidy not possible due to absence of metaphases | 7 (20%) |
| Endoreduplication/masked hypodiploid | |
| t (1:19) | 1 (3%) |
| TCF3-PBX1 | 1 (3%) |
| Characteristic . | All patients (N = 34) . |
|---|---|
| Age, median (range), y | 20 (15-52) |
| Age 15-25 y | 24 |
| Age <35 y | 28 |
| Age >35 y | 6 |
| Risk group | |
| Standard risk | 14 (41%) |
| High risk | 20 (59%) |
| Male:female sex | 26:8 |
| ECOG performance status >1 | 6 (17.6%) |
| White blood cell count ≥30 × 109/L | 7 (20.6%) (range, 30-70 × 109/L) |
| CNS involvement | 10 (29.4%) |
| Flow cytometry alone | 10 (29.4%) |
| Cytomorphology and flow cytometry | 5 (14.7%) |
| CD20%, median (range) | 75% (20%-100%) |
| Cytogenetic features | |
| Diploid | 12 (34%) |
| Hyperdiploidy | 9 (25%) |
| Hypodiploidy | 6 (17%) |
| Ploidy not possible due to absence of metaphases | 7 (20%) |
| Endoreduplication/masked hypodiploid | |
| t (1:19) | 1 (3%) |
| TCF3-PBX1 | 1 (3%) |
ECOG, Eastern Cooperative Oncology Group.